Use of Medicinal Plants and Other Alternative and Complementary Medicines by Patients With Cancer in Reunion Island (CAMUCRI)

Evaluation of the Use of Medicinal Plants and Other Alternative and Complementary Medicines by Patients With Cancer in Reunion Island

Exploratory, observational and cross-sectional study with the aim of describing the use of plants for medicinal purposes (and other Complementary and Alternative Medicine) and identifying the determinants of this use. The methodology envisaged is mixed with an exploratory design combining qualitative (interviews) and quantitative techniques (questionnaires).

To knowledge of investigators, no study has been carried out in Reunion Island on the use of plants and other alternative and complementary medicines among cancer patients.

Study Overview

• Status: Recruiting
• Conditions: Cancer

• Study Type: Observational
• Enrollment (Anticipated): 520

Contacts and Locations

• Study Contact: Name: Florent DRAPEAU, PharmD; Phone Number: 02 62 35 90 00; Email: florent.drapeau@chu-reunion.fr
• Study Contact Backup: Name: Laetitia BERLY; Phone Number: 02 62 90 62 86; Email: laetitia.berly@chu-reunion.fr

Study Locations

• Réunion
  • Saint-Denis, Réunion, 97400
    • Recruiting
    • CHU La Réunion
    • Contact: Florent DRAPEAU, PharmD; Phone Number: 02 62 35 90 00; Email: florent.drapeau@chu-reunion.fr
    • Principal Investigator: Patricia ZUNIC, MD
  • Sainte-Clotilde, Réunion, 97490
    • Not yet recruiting
    • Clinique Saint Clotilde
    • Contact: Antoine MORICEAU, PharmD; Email: antoine.moriceau@clinifutur.net
    • Principal Investigator: Gilles BAUMONT, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with cancer linving in the Reunion Island

Description

Inclusion Criteria:

• Living in Reunion Island
• Suffering from cancer (solid tumors, hematological malignancies)
• Able to answer a questionnaire
• Patient who does not oppose to the research

Exclusion Criteria:

• Person of legal age under guardianship or under legal protection
• Persons who do not understand French or Reunionese Creole

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Qualitative group; Interview about the use of Complementary and Alternative Medecine
Quantitative group; Questionnaire about the use of Complementary and Alternative Medecine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Use of herbal medicine	Proportion of patients using herbal medicine (from the patient's perspective) among cancer patients.	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Barriers of dialogue between patient and practionner	Interviews between patient and interviewer will help to extract the barriers limiting patient/practitioner dialogue on Complementary and Alternative Medicine use from patient and practitioner perspectives	Day 1
Need for Information on Complementary and Alternative Medicine	Interviews between patient and interviewer will help to find out expectations about the need for information on Complementary and Alternative Medicine use from the patient's perspective and from the practitioner's perspective	Day 1
Improving questionnaire after the practionners' focus group	A practionners' focus group will be organised after the interviews to review the feedbacks and opinions on the questionnaire to improve the questionnaire for the quantitative part of the study	Day 1

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de la Réunion
• Collaborators: APLAMEDOM

Study record dates

Study Major Dates

• Study Start (Anticipated): April 1, 2022
• Primary Completion (Anticipated): April 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: May 18, 2021
• First Submitted That Met QC Criteria: June 18, 2021
• First Posted (Actual): June 21, 2021

Study Record Updates

• Last Update Posted (Actual): April 8, 2022
• Last Update Submitted That Met QC Criteria: March 31, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: 2021/CHU/05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No